Reneo Pharmaceuticals Competitors

Reneo Pharmaceuticals (NASDAQ:RPHM) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Reneo Pharmaceuticals and Pharming Group's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Reneo Pharmaceuticals and Pharming Group's revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Reneo Pharmaceuticals and Pharming Group, as provided by MarketBeat.

Reneo Pharmaceuticals presently has a consensus price target of $31.3333, indicating a potential upside of 287.79%. Given Reneo Pharmaceuticals' higher probable upside, research analysts plainly believe Reneo Pharmaceuticals is more favorable than Pharming Group.

Summary

Reneo Pharmaceuticals beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Reneo Pharmaceuticals (NASDAQ:RPHM) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Valuation & Earnings

This table compares Reneo Pharmaceuticals and Vor Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Reneo Pharmaceuticals and Vor Biopharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Reneo Pharmaceuticals and Vor Biopharma, as provided by MarketBeat.com.

Reneo Pharmaceuticals presently has a consensus target price of $31.3333, suggesting a potential upside of 287.79%. Vor Biopharma has a consensus target price of $48.20, suggesting a potential upside of 151.83%. Given Reneo Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Reneo Pharmaceuticals is more favorable than Vor Biopharma.

Summary

Reneo Pharmaceuticals beats Vor Biopharma on 2 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Pharvaris B.V. and Reneo Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Pharvaris B.V. and Reneo Pharmaceuticals' revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Pharvaris B.V. and Reneo Pharmaceuticals, as provided by MarketBeat.com.

Pharvaris B.V. presently has a consensus price target of $47.50, indicating a potential upside of 113.48%. Reneo Pharmaceuticals has a consensus price target of $31.3333, indicating a potential upside of 287.79%. Given Reneo Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Pharvaris B.V..

Summary

Reneo Pharmaceuticals beats Pharvaris B.V. on 2 of the 2 factors compared between the two stocks.

Reneo Pharmaceuticals (NASDAQ:RPHM) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Valuation and Earnings

This table compares Reneo Pharmaceuticals and 4D Molecular Therapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent recommendations for Reneo Pharmaceuticals and 4D Molecular Therapeutics, as provided by MarketBeat.

Reneo Pharmaceuticals currently has a consensus target price of $31.3333, suggesting a potential upside of 287.79%. 4D Molecular Therapeutics has a consensus target price of $45.50, suggesting a potential upside of 69.46%. Given Reneo Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Reneo Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Profitability

This table compares Reneo Pharmaceuticals and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Summary

Reneo Pharmaceuticals beats 4D Molecular Therapeutics on 3 of the 3 factors compared between the two stocks.

Bolt Biotherapeutics (NASDAQ:BOLT) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares Bolt Biotherapeutics and Reneo Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Bolt Biotherapeutics and Reneo Pharmaceuticals' top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Bolt Biotherapeutics and Reneo Pharmaceuticals, as reported by MarketBeat.

Bolt Biotherapeutics presently has a consensus price target of $41.00, suggesting a potential upside of 124.66%. Reneo Pharmaceuticals has a consensus price target of $31.3333, suggesting a potential upside of 287.79%. Given Reneo Pharmaceuticals' higher possible upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Bolt Biotherapeutics.

Gracell Biotechnologies (NASDAQ:GRCL) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Gracell Biotechnologies and Reneo Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and price targets for Gracell Biotechnologies and Reneo Pharmaceuticals, as provided by MarketBeat.

Gracell Biotechnologies presently has a consensus target price of $34.50, suggesting a potential upside of 233.98%. Reneo Pharmaceuticals has a consensus target price of $31.3333, suggesting a potential upside of 287.79%. Given Reneo Pharmaceuticals' higher probable upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Gracell Biotechnologies.

Valuation and Earnings

This table compares Gracell Biotechnologies and Reneo Pharmaceuticals' revenue, earnings per share and valuation.